Document Type

Article

Version Deposited

Published Version

Publication Date

1-1-2019

Publication Title

Schizophrenia Bulletin

DOI

10.1093/schbul/sby021

Abstract

Blood-based biomarker discovery for psychotic disorders has yet to impact upon routine clinical practice. In physical disorders antibodies have established roles as diagnostic, prognostic and predictive (theranostic) biomarkers, particularly in disorders thought to have a substantial autoimmune or infective aetiology. Two approaches to antibody biomarker identification are distinguished: a "top-down" approach, in which antibodies to specific antigens are sought based on the known function of the antigen and its putative role in the disorder, and emerging "bottom-up" or "omics" approaches that are agnostic as to the significance of any one antigen, using high-throughput arrays to identify distinctive components of the antibody repertoire. Here we review the evidence for antibodies (to self-antigens as well as infectious organism and dietary antigens) as biomarkers of diagnosis, prognosis, and treatment response in psychotic disorders. Neuronal autoantibodies have current, and increasing, clinical utility in the diagnosis of organic or atypical psychosis syndromes. Antibodies to selected infectious agents show some promise in predicting cognitive impairment and possibly other symptom domains (eg, suicidality) within psychotic disorders. Finally, infectious antibodies and neuronal and other autoantibodies have recently emerged as potential biomarkers of response to anti-infective therapies, immunotherapies, or other novel therapeutic strategies in psychotic disorders, and have a clear role in stratifying patients for future clinical trials. As in nonpsychiatric disorders, combining biomarkers and large-scale use of "bottom-up" approaches to biomarker identification are likely to maximize the eventual clinical utility of antibody biomarkers in psychotic disorders.

Comments

Copyright © The Author(s) 2018. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Published Citation

Pollak TA, Rogers JP, Nagele RG, Peakman,M, Stone JM, David AS, McGuire P. Antibodies in the diagnosis, prognosis and prediction of psychotic disorders. Schizophrenia Bulletin. 2019 Jan 1;45(1):233-246. E-pub 2018 Feb 21. doi: 10.1093/schbul/sby021. PMID: 29474698. PMCID: PMC6293207.

Share

COinS